LADA patients with GAD65-M+Cabs (C-terminal and middle region of the GAD65 protein) have clinical features similar to those of T1D patients, and GAD65-CAb appears to confer a higher risk of the development of lower serum C-peptide levels and the requirement for insulin therapy (8–11). This evidence concerns the gene INS and type 1 diabetes mellitus.